Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061945 · ClinicalTrials.gov registry record · Phase 1
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 302
- Enrollment target
NCT00061945: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00061945 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 302 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00061945, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 302 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of alemtuzumab when given together with combination chemotherapy and to see how well it works in treating patients with untreated acute lymphoblastic leukemia. Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy also work in different ways to kill cancer cells or stop them from growing. Giving alemtuzumab together with combination chemotherapy may be a better way to block cancer growth.
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG vincristine sulfate
- DRUG allopurinol
- DRUG daunorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2003-06 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00061945
The ClinicalTrials.gov registry entry for NCT00061945 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00061945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00061945 about?
NCT00061945 is a clinical study titled "Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia". This phase I/II trial studies the side effects and best dose of alemtuzumab when given together with combination chemotherapy and to see how well it works in treating patients with untreated acute lymphoblastic leukemia. Monoclonal antibodies, such as alemtuzumab, can block cancer growth in differen...
What is the current status of trial NCT00061945?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 302 participants. The study started on 2003-06. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00061945?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), vincristine sulfate (DRUG), allopurinol (DRUG), daunorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00061945?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.